<DOC>
	<DOCNO>NCT00003639</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Interferon alfa may interfere growth cancer cell slow growth non-Hodgkin 's lymphoma . It yet know whether combine one chemotherapy drug interferon alfa effective chemotherapy alone treat patient low-grade non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without interferon alfa treat patient low-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Interferon Alfa Treating Patients With Low-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare remission induction rate toxicity chlorambucil plus dexamethasone without idarubicin patient stage II-IV low grade non-Hodgkin 's lymphoma . II . Assess additional value period consolidation/maintenance treatment utilize low dose interferon alfa standard dose interferon alfa versus treatment relationship duration event-free survival patient . OUTLINE : This randomize , open label , control , multicenter study . Patients randomize one two arm induction chemotherapy . Arm I : Patients receive oral chlorambucil three time daily 3 consecutive day , oral idarubicin daily 3 consecutive day , oral dexamethasone twice daily 5 consecutive day every 21 day . Arm II : Patients receive oral chlorambucil three time daily 3 consecutive day oral dexamethasone twice daily 5 consecutive day every 21 day . Treatment arm continue 6 course absence disease progression unacceptable toxicity . After 6 course chemotherapy , patient reassess . If achieve maximal complete response good partial response , patient randomize one three arm . Arm I : Patients receive treatment disease progress . Arm II : Patients receive low dose interferon alfa subcutaneously three time per week maximum 3 year absence disease progression . Arm III : Patients receive standard dose interferon alfa subcutaneously three time week maximum 3 year absence disease progression . Patients follow every 8-12 week 3 year . PROJECTED ACCRUAL : There 200 patient accrue study approximately 150 patient enter second phase study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm B cell low grade nonHodgkin 's lymphoma Stage II , III IV Measurable disease No chronic lymphatic leukemia , prolymphocytic leukemia hairy cell leukemia , angioimmunoblastic lymphadenopathy , mycosis fungoides , Sezary 's syndrome Tzone lymphoma , plasmacytoma , T cell lymphoma , centroblastic lymphoma No CNS disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 15 70 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 2,000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 1.96 mg/dL AST/ALT great 2 time upper limit normal Renal : Creatinine great 1.65 mg/dL OR Creatinine clearance great 40 mL/min Cardiovascular : No history myocardial infarction past 12 month No severe uncontrolled cardiac failure Other : No history malignant disease except basal cell carcinoma carcinoma situ cervix No active peptic ulceration , significant dyspepsia , history hematemesis melena No concurrent medical psychological condition may preclude study participation Not pregnant Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior extensive radiotherapy malignant disease Prior radiotherapy localize disease subsequently relapse permitted Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>